---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-125166"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2026-11-10T21:07:06+00:00"
generated_at: "2026-11-10T21:09:28.176113+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PacBio signs $100M at-the-market stock sales agreement with Allen & Company

## Summary
- Sales Agreement dated Nov 10, 2026 lets PacBio sell up to $100,000,000 of common stock (PACB) from time to time through an at-the-market program.
- Allen & Company LLC acts as sales agent and is paid up to 3.0% of aggregate gross proceeds from shares it sells.
- Either party may terminate on 10 days' notice; Allen may terminate immediately on certain events, including a material adverse change.
- Shares are issued under the automatic shelf Form S-3ASR (File No. 333-293751) filed Feb 25, 2026; prospectus supplement filed Nov 10, 2026.
- PacBio has no obligation to sell and controls share count, timing, daily limits and minimum price; it may suspend offers at any time.

## SEC filing metadata
- accession: 0001104659-26-125166
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2026-11-10T21:07:06+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000110465926125166/0001104659-26-125166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000110465926125166/tm2629325d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-125166
- JSON: https://secwatch.observer/filing/0001104659-26-125166.json
- Plain text: https://secwatch.observer/filing/0001104659-26-125166.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.